Which of the following recommendations would be most appropriate when discussing a change in therapy from Exjade (deferasirox) to Jadenu (deferasirox) with a healthcare provider?
1) There is no need to monitor renal function with Jadenu
2) The Jadenu dose should be started at a dosage 30
3) Dosing is based on equivalent mg/kg dosing parameters
4) The Jadenu dose should be started at a dosage 30